OMA BOT Book 4.24.2024

A. Fitch et al.

Obesity Pillars 6 (2023) 100061

Acknowledgements and Funding

[6] Francavilla C, Andrick R. Obesity medicine association (OMA): advocacy update. Obesity Pillars 2022;1:100003.

This manuscript received no funding.

Angela Fitch a , Anthony Auriemma b , Harold Edward Bays c , * a Knownwell, 15 Oak St Suite 3, Needham, MA, 02492, USA b Ascension Illinois Medical Group Weight Loss Solutions, 25 E, Schaumburg Rd, Suite 101, Schaumburg, IL, 60194, USA c Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, 3288 Illinois Avenue, Louisville, KY, 40213, USA

References

[1] Carvalho M, Almeida IF. The role of pharmaceutical compounding in promoting medication adherence. Pharmaceuticals (Basel) 2022;15. [2] Kim JC, Park EJ, Na DH. Gastrointestinal permeation enhancers for the development of oral peptide pharmaceuticals. Pharmaceuticals (Basel) 2022;15. [3] Allen Jr LV. Basics of compounding: basics of compounding with organic salts. Int J Pharm Compd 2010;14:322 – 6. [4] Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022. Obesity Pillars 2022:100018. [5] Morrow T, Felcone LH. De fi ning the difference: what makes biologics unique. Bio technol Healthc 2004;1:24 – 9.

* Corresponding author. E-mail addresses: dr fi tch@knownwell.health (A. Fitch), anthonyauriemma123@gmail.com (A. Auriemma), hbaysmd@outlook.com (H.E. Bays).

3